Skip to main content

Advertisement

SpringerLink
Log in

Memory Assessment in Studies of Cognition-Enhancing Drugs for Alzheimer’s Disease

  • Review Article
  • Published:
Drugs & Aging Aims and scope Submit manuscript

Abstract

There is an increasing number of cognition-enhancing drugs for Alzheimer’s Disease (AD) and, consequently, drug trials represent a growing field of interest in research. As memory dysfunction is generally the first and most severe cognitive impairment in AD, the choice of memory testing to be used in these studies is of great importance. It should reflect an understanding of memory systems being assessed with neuropsychological tests and the fact that some tests can be more appropriate than others to show benefit with certain classes of cognition-enhancing drugs.

Severe deterioration of episodic and semantic memory occurs very early in the AD process while working memory shows a gradual deterioration over time. Some aspects of working and implicit memory can be spared in the mild to moderate stages of AD. Tests of working, episodic, semantic and implicit memory are used as outcomes in trials with acetylcholinesterase inhibitors, drugs with other neurotransmitter strategies, metabolic enhancers and drugs which may impact upon a variety of CNS processes. The clinical scales and observational measures are largely used in trials of cognition-enhancing drugs for AD (46.66% of all the studies reviewed).

The Digit Span test, the Rey Auditory Verbal Learning Test, the Buschke Selective Reminding Test and the verbal fluency tasks are the most sensitive memory tests, whereas the most sensitive scales are the Sandoz Clinical Assessment-Geriatric, the Gottfried-Bräne-Steel scale and the Blessed Dementia Scale. Finally, we suggest that future investigations should use sensitive memory tests, together with behavioural and psychiatric scales, rather than general observational evaluations.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Subscribe and save

Springer+ Basic
$34.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or eBook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Van Reekum R, Black S, Conn D, et al. Cognition enhancing drugs in dementia: a guide to the future. Can J Psychiatry 1997; 42Suppl. 1: 35S–50S

    PubMed  Google Scholar 

  2. Ravizza L, Ferrero P, Eva C, et al. Peripheral cholinergic changes and pharmacological aspects in Alzheimer’s disease. In: Giacobini E, Becker R, editors. Current research in Alzheimer therapy. New York: Taylor and Francis, 1988; 355–63

    Google Scholar 

  3. Pettegrew JW, Klunk WE, Panchalingam K, et al. Clinical and neurochemical effects of acetyl-L-carnitine in Alzheimer’s disease. Neurobiol Aging 1995; 16(1): 1–4

    PubMed  CAS  Google Scholar 

  4. Yamagami S, Hirayama E, Mui K, et al. The clinical efficacy of nicergoline against psychotic symptoms in dementia. Curr Ther Res 1992; 51(4): 529–35

    Google Scholar 

  5. Saletu B, Moller HJ, Grunberger J, et al. Propentofylline in adult-onset cognitive disorders: double-blind, placebo-controlled, clinical, psychometric and brain mapping studies. Neuropsychobiology 1990; 24(4): 173–84

    PubMed  Google Scholar 

  6. Moller HJ, Maurer I, Saletu B. Placebo-controlled trial of the xanthine derivative propentofylline in dementia. Pharmacopsychiatry 1994; 27: 159–65

    PubMed  CAS  Google Scholar 

  7. Weingartner H, Kaye W, Gold P, et al. Vasopressin treatment of cognitive dysfunction in progressive dementia. Life Sci 1981; 29: 2721–6

    PubMed  CAS  Google Scholar 

  8. Fillit H, Weinreb H, Cholst I, et al. Observations in a preliminary open trial of estradiol therapy for senile dementia: Alzheimer’s type. Psychoneuroendocrinology 1986; 11(3): 337–45

    PubMed  CAS  Google Scholar 

  9. Alhainen K, Riekkinen PJ Sr. Discrimination of Alzheimer patients responding to cholinesterase inhibitor therapy. Acta Neurol Scand 1993; 149 Suppl.: 16–21

    CAS  Google Scholar 

  10. Tariot PN, Sunderland T, Weingartner H, et al. Cognitive effects of L-deprenyl in Alzheimer’s disease. Psychopharmacology 1987; 91: 489–95

    PubMed  CAS  Google Scholar 

  11. Smith RC, Vroulis G, Johnson R, et al. Comparison of therapeutic response to long-term treatment with lecithin versus piracetam plus lecithin in patients with Alzheimer’s disease. Psychopharmacol Bull 1984; 20(3): 542–5

    PubMed  CAS  Google Scholar 

  12. Caamano J, Gomez MJ, Franco A, et al. Effects of CDP-choline on cognition and cerebral hemodynamics in patients with Alzheimer’s disease. Methods Find Exp Clin Pharmacol 1994; 16(3): 211–8

    PubMed  CAS  Google Scholar 

  13. Tulving E. Elements of episodic memory. Oxford: Oxford University Press, 1983

    Google Scholar 

  14. Squire LR. Memory and brain. New York/Oxford: Oxford University Press, 1987

    Google Scholar 

  15. Morris RG, Baddeley AD. Comment: primary and working memory functioning in Alzheimer-type dementia. J Clin Exp Neuropsychol 1988; 10(2): 279–96

    PubMed  CAS  Google Scholar 

  16. Baddeley AD. Working memory. 2nd ed. Oxford: Oxford University Press, 1991

    Google Scholar 

  17. Dalla Barba G, Goldblum MC. The influence of semantic encoding on recognition memory in Alzheimer’s disease. Neuropsychologia 1996; 34(12): 1181–6

    PubMed  Google Scholar 

  18. Craik FIM. On the transfer of information from temporary to permanent memory. Philos Trans R Soc Lond B 1983; 302: 341–59

    Google Scholar 

  19. Jacoby LL. Perceptual enhancement: persistent effect of an experience. J Exp Psychol Learn Mem Cogn 1983; 9: 21–38

    PubMed  CAS  Google Scholar 

  20. Moscovitsch M, Winocur G, McLachlan D. Memory as assessed by recognition and reading time in normal and memory impaired people with Alzheimer’s disease and other neurological disorders. J Exp Psychol Gen 1986; 115: 331–47

    Google Scholar 

  21. Warrington E, McCarthy RA. The fractionation of retrograde amnesia. Brain Cogn 1988; 7: 184–200

    PubMed  CAS  Google Scholar 

  22. Wilson B, Baddeley AD. Semantic, episodic, and autobiographical memory in a postmeningitic amnesic patient. Brain Cogn 1988; 8: 31–46

    PubMed  CAS  Google Scholar 

  23. Crosson B. Subcortical functions in language and memory. New York/London: Guilford Press, 1992

    Google Scholar 

  24. Simard M. Review: a global view of the subcortical structures involvement in cognition? Brain Cogn 1994; 26: 73–90

    Google Scholar 

  25. Baddeley AD, Hitch G. Working memory. In: Bower IGA, editor. The psychology of learning and motivation. New York: Academic Press, 1974: 47–90

    Google Scholar 

  26. Baddeley AD. Working memory. Oxford: Oxford University Press, 1986

    Google Scholar 

  27. Morris RG, Kopelman M. The memory deficits in Alzheimer-type dementia: a review. Q J Exp Psychol 1986; 38A: 575–602

    Google Scholar 

  28. Baddeley AD, Delia Sala S. Working memory and executive control. Philos Trans R Soc Lond B 1996; 351: 1397–404

    CAS  Google Scholar 

  29. Baddeley AD, Logie R, Bressi S, et al. Dementia and working memory. Q J Exp Psychol 1986; 38A: 603–18

    Google Scholar 

  30. Baddeley AD, Bressi S, Della Sala S, et al. The decline of working memory in Alzheimer’s disease: a longitudinal study. Brain 1991; 114: 2521–42

    PubMed  Google Scholar 

  31. Baddeley AD, Della Sala S, Papagno C, et al. Dual task performance in dysexecutive and non-dysexecutive patients with a frontal lesion. Neuropsychology 1997; 11(2): 187–94

    PubMed  CAS  Google Scholar 

  32. Greene JDW, Hodges JR, Baddeley AD. Autobiographical memory and executive function in early dementia of the Alzheimer type. Neuropsychologia 1995; 33(12): 1647–70

    PubMed  CAS  Google Scholar 

  33. Wechsler D. WAIS-R Manual. New York: Psychological Corporation, 1981

    Google Scholar 

  34. Flicker C, Ferris SH, Reisberg B. A two-year longitudinal study of cognitive function in normal aging and Alzheimer’s disease. J Geriatr Psychiatry Neurol 1993; 6: 84–96

    PubMed  CAS  Google Scholar 

  35. Linn RT, Wolf PA, Bachman DL, et al. The preclinical phase of probable Alzheimer’s disease. Arch Neurol 1995; 52: 485–90

    PubMed  CAS  Google Scholar 

  36. Riekkinen M, Soininen H, Riekkinen P, et al. Tetrahydro-aminoacridine improves the recency effect in Alzheimer’s disease. Neuroscience 1998; 83(2): 471–9

    PubMed  CAS  Google Scholar 

  37. Schacter DL. Implicit expression of memory in organic amnesia: learning of new facts and associations. Hum Neurobiol 1987; 6: 107–18

    PubMed  CAS  Google Scholar 

  38. Schacter DL. Implicit memory: history and current status. J Exp Psychol Learn Mem Cogn 1987; 13: 501–18

    Google Scholar 

  39. Tulving E. Precis of elements of episodic memory. Behav Brain Sci 1984; 7: 223–68

    Google Scholar 

  40. Kopelman MD, Wilson BA, Baddeley AD. The autobiographical memory interview: a new assessment of autobiographical and personal semantic memory in amnesic patients. J Clin Exp Neuropsychol 1989; 11(5): 724–44

    PubMed  CAS  Google Scholar 

  41. Kopelman MD. Frontal dysfunction and memory deficits in the alcoholic Korsakoff syndrome and Alzheimer-type dementia. Brain 1991; 114: 117–37

    PubMed  Google Scholar 

  42. Tiberghien G. Psychologie de la mémoire humaine. In: Bruyer R, Van der Linden M, editors. Neuropsychologie de la mémoire humaine. Grenoble: Presses Universitaires de Grenoble, 1991: 9–37

    Google Scholar 

  43. Boller F, Deweer B. Troubles de la mémoire dans les démences. In: Bruyer R, Van der Linden M, editors. Neuropsychologie de la mémoire humaine. Grenoble: Presses Universitaires de Grenoble, 1991: 89–107

    Google Scholar 

  44. Sahakian BJ, Morris RG, Evenden JL, et al. A comparative study of visuospatial memory and learning in Alzheimer-type dementia and Parkinson’s disease. Brain 1988; 111: 695–718

    PubMed  Google Scholar 

  45. Deweer B, Ergis AM, Fossati P, et al. Explicit memory, procedural learning and lexical priming in Alzheimer’s disease. Cortex 1994; 30: 113–26

    PubMed  CAS  Google Scholar 

  46. Goldman WP, Winograd E, Goldstein FC, et al. Source memory in mild to moderate Alzheimer’s disease. J Clin Exp Neuropsychol 1994; 16(1): 105–16

    PubMed  CAS  Google Scholar 

  47. Ergis AM, Van der Linden M, Deweer B. Cross-form priming in normal aging and in mild dementia of the Alzheimer type. Cortex 1995; 31: 699–710

    PubMed  CAS  Google Scholar 

  48. Hodges JR, Patterson K. Is semantic memory consistently impaired early in the course of Alzheimer’s disease? Neuroanatomical and diagnostic implications. Neuropsychologia 1995; 33(4): 441–59

    PubMed  CAS  Google Scholar 

  49. Herlitz A, Small BJ, Fratiglioni L, et al. Detection of mild dementia in community surveys: is it possible to increase the accuracy of our instruments? Arch Neurol 1997; 54: 319–24

    PubMed  CAS  Google Scholar 

  50. Buschke H, Sliwinski M, Kuslansky G, et al. Aging, encoding specificity, and memory change in the double memory test. J Int Neuropsychol Soc 1995; 1: 483–93

    PubMed  CAS  Google Scholar 

  51. Buschke H, Sliwinski MJ, Kuslansky G, et al. Diagnosis of early dementia by the double memory test: encoding specificity improves diagnostic sensitivity and specificity. Neurology 1997; 48: 989–97

    PubMed  CAS  Google Scholar 

  52. Howard D, Patterson K. Pyramids and palm trees: a test of semantic access from pictures and words. Bury St Edmunds: Thames Valley Publishing Company, 1992

    Google Scholar 

  53. Persson G, Skoog I. Subclinical dementia: relevance of cognitive symptoms and signs. J Geriatr Psychiatry Neurol 1992; 5: 172–8

    PubMed  CAS  Google Scholar 

  54. Chan AS, Salmon DP, Butters N, et al. Semantic network abnormality predicts rate of cognitive decline in patients with probable Alzheimer’s disease. J Int Neuropsychol Soc 1995; 1: 297–303

    PubMed  CAS  Google Scholar 

  55. Flicker C, Ferris SH, Crook T, et al. Implications of memory and language dysfunction in the naming deficit of senile dementia. Brain Lang 1987; 31: 187–200

    PubMed  CAS  Google Scholar 

  56. Dritschel BH, Williams JMG, Baddeley AD, et al. Autobiographical fluency: a method for the study of personal memory. Mem Cogn 1992; 20(2): 133–40

    CAS  Google Scholar 

  57. Sagar HJ, Cohen NJ, Sullivan EV, et al. Remote memory function in Alzheimer’s disease and Parkinson’s disease. Brain 1988; 111: 185–206

    PubMed  Google Scholar 

  58. Huppert FA, Beardsall L. Prospective memory impairement as an early indicator of dementia. J Clin Exp Neuropsychol 1994; 15(5): 805–21

    Google Scholar 

  59. Sinnott JD. Prospective/intentional memory and aging: memory as adaptative action. In: Poon LM, Rubin D, Wilson BA, editors. Cognition in everyday life. New Rochelle: Cambridge University Press, 1989

    Google Scholar 

  60. Wilson B, Cockburn J, Baddeley AD. The Rivermead behavioural memory test. Reading: Thames Valley Test Company, 1985

    Google Scholar 

  61. McKitrick LA, Camp CJ, Black FW. Prospective memory intervention in Alzheimer’s disease. J Gerontol 1992; 47(5): 337–43

    Google Scholar 

  62. Eslinger PJ, Damasio AR. Preserved motor learning in Alzheimer’s disease: implications for anatomy and behavior. J Neurosci 1986; 6(10): 3006–9

    PubMed  CAS  Google Scholar 

  63. Grafton ST, Mazziotta JC, Presty S, et al. Functional anatomy of human procedural learning determined with regional cerebral blood flow and PET. J Neurosci 1992; 12(7): 2542–8

    PubMed  CAS  Google Scholar 

  64. Deweer B, Pillon B, Michon A, et al. Mirror reading in Alzheimer’s disease: normal skill learning and acquisition of item-specific information. J Clin Exp Neuropsychol 1993; 15(5): 789–804

    PubMed  CAS  Google Scholar 

  65. Russo R, Spinnler H. Implicit verbal memory in Alzheimer’s disease. Cortex 1994; 30: 359–75

    PubMed  CAS  Google Scholar 

  66. Keane MM, Gabrieli JDE, Mapstone HC, et al. Double dissociation of memory capacities after bilateral occipital-lobe or medial temporal-lobe lesions. Brain 1995; 118: 1129–48

    PubMed  Google Scholar 

  67. Fleischman DA, Gabrieli JDE, Rinaldi JA, et al. Word-stem completion priming for perceptually and conceptually encoded words in patients with Alzheimer’s disease. Neuropsychologia 1996; 35(1): 25–35

    Google Scholar 

  68. Roediger HLI, Blaxton TA. Effects of varying modality, surface features, and retention interval on word fragment completion. Mem Cognit 1987; 15: 379–88

    PubMed  Google Scholar 

  69. Tulving E, Schacter DL. Priming and human memory systems. Science 1990; 247:310–6

    Google Scholar 

  70. Gabrieli JDE, Keane MM, Stanger BZ, et al. Dissociations among structural-perceptual, lexical-semantic, and event-fact memory systems in Alzheimer, amnesic, and normal subjects. Cortex 1994; 30: 75–103

    PubMed  CAS  Google Scholar 

  71. Kaszniak AW, Christenson GDT. Self-awareness of deficit in patients with Alzheimer’s disease. In: Hameroff SR, Kaszniak AW, Scott AC, editors. Toward a science of consciousness. Cambridge: MIT Press, 1996: 227–42

    Google Scholar 

  72. Dubois B, Levy R, Verin M, et al. Experimental approach to prefrontal functions in humans. In: Grafman J, Holyoak KJ, Boller F, editors. Structure and functions of the human prefrontal cortex. New York: New York Academy of Sciences, 1995: 41–60

    Google Scholar 

  73. Goldman-Rakic PS. Architecture of the prefrontal cortex and the central executive. In: Grafman J, Holyoak KJ, Boller F, editors. Structure and functions of the human prefrontal cortex. New York: New York Academy of Sciences, 1995: 71–83

    Google Scholar 

  74. Stuss DT, Shallice T, Alexander MP, et al. A multidisciplinary approach to anterior attentional functions. In: Grafman J, Holyoak KJ, Boller F, editors. Structure and functions of the human prefrontal cortex. New York: New York Academy of Sciences, 1995: 191–211

    Google Scholar 

  75. Malapani C, Pillon B, Dubois B, et al. Impaired simultaneous cognitive task performances in Parkinson’s disease: a dopaminerelated dysfunction. Neurology 1994; 44: 319–26

    PubMed  CAS  Google Scholar 

  76. Coull JT, Middleton HC, Robbins TW, et al. Contrasting effects of Clonidine and diazepam on tests of working memory and planning. Psychopharmacology 1995; 120: 311–21

    PubMed  CAS  Google Scholar 

  77. Paulesu E, Frith CD, Frackowiak RSJ. The neural correlates of the verbal component of working memory. Nature 1993; 362: 342–5

    PubMed  CAS  Google Scholar 

  78. Cohen JD, Forman SD, Braver TS, et al. Activation of the prefrontal cortex in a nonspatial working memory task with functional MRI. Hum Brain Mapping 1994; 1: 293–304

    Google Scholar 

  79. Stern Y, Andrews H, Pittman J, et al. Diagnosis of dementia in a heterogeneous population: development of a neuropsychological paradigm-based diagnosis of dementia and quantified correction for the effects of education. Arch Neurol 1992; 49: 453–60

    PubMed  CAS  Google Scholar 

  80. Ruchkin DS, Jr Johnson R, Grafman J, et al. Multiple visuospatial working memory buffers: evidence from spatiotemporal patterns of brain activity. Neuropsychologia 1997; 35(2): 195–209

    PubMed  CAS  Google Scholar 

  81. Jonides J, Smith EE, Koeppe RA, et al. Spatial working memory in humans as revealed by PET. Nature 1993; 363: 623–5

    PubMed  CAS  Google Scholar 

  82. McCarthy G, Blamire AM, Puce A, et al. Functional magnetic resonance imaging of human prefrontal cortex activation during a spatial working memory task. Proc Natl Acad Sci U S A 1994; 91: 8690–4

    PubMed  CAS  Google Scholar 

  83. Christensen H, Maltby N, Jorm AF, et al. Cholinergic blockade as a model of the cognitive deficits in Alzheimer’s disease. Brain 1992; 115: 1681–99

    PubMed  Google Scholar 

  84. Petrides M. Frontal lobes and memory. In: Boller F, Grafman J, editors. Handbook of Neuropsychology. New York: Elsevier, 1989; 3: 75–90

    Google Scholar 

  85. Squire LR, Zola-Morgan S. The medial temporal lobe memory system. Science 1991; 253: 1380–6

    PubMed  CAS  Google Scholar 

  86. Signoret JL. Neuroanatomie de la mémoire. In: Bruyer R, Van der Linden M, editors. Neuropsychologie de la mémoire humaine. Grenoble: Presses Universitaires de Grenoble, 1991: 39–50

    Google Scholar 

  87. Forette F, Bert P, Breuil V, et al. Therapeutic drug trials and heterogeneity of Alzheimer’s disease. In: Boller F, Forette F, Khatchaturian Z, et al., editors. Heterogeneity of Alzheimer’s disease: research and perspectives in Alzheimer’s disease. Berlin: Springer-Verlag, 1992: 67–73

    Google Scholar 

  88. Kapur N, Young A, Bateman D, et al. Focal retrograde amnesia: a long term clinical and neuropsychological follow-up. Cortex 1989; 25: 387–402

    PubMed  CAS  Google Scholar 

  89. Kapur N, Ellison D, Smith MP, et al. Focal retrograde amnesia following bilateral temporal lobe pathology. Brain 1992; 115: 73–85

    PubMed  Google Scholar 

  90. Kapur N, Ellison D, Parkin AJ, et al. Bilateral temporal lobe pathology with sparing of medial temporal lobe structures: lesion profile and pattern of memory disorder. Neuropsychologia 1994; 32(1): 23–38

    PubMed  CAS  Google Scholar 

  91. De Renzi E, Lucchelli F. Dense retrograde amnesia, intact learning capability and abnormal forgetting rate: a consolidation deficit? Cortex 1993; 29: 449–66

    PubMed  Google Scholar 

  92. Hunkin NM, Parkin AJ, Bradley VA, et al. Focal retrograde amnesia following closed head injury: a case study and theoretical account. Neuropsychologia 1995; 33(4): 509–23

    PubMed  CAS  Google Scholar 

  93. Goldberg E, Antin SP, Bilder RM, et al. Retrograde amnesia: possible role of mesencephalic reticular activation in long-term memory. Science 1981; 213: 1392–4

    PubMed  CAS  Google Scholar 

  94. Summers WK, Majovski LV, Marsh GM, et al. Oral tetra-hydroaminoacridine in long-term treatment of senile dementia, Alzheimer type. N Engl J Med 1986; 315(20): 1241–5

    PubMed  CAS  Google Scholar 

  95. Davis KL, Thal LJ, Gamzu ER, The Tacrine Collaborative Study group, et al. A double-blind, placebo-controlled multi-center study of tacrine for Alzheimer’s disease. N Engl J Med 1992; 327(18): 1253–9

    PubMed  CAS  Google Scholar 

  96. Farlow M, Gracon SI, Hershey LA, The Tacrine Study Group, et al. A controlled trial of tacrine in Alzheimer’s disease. JAMA 1992; 268(18): 2523–9

    PubMed  CAS  Google Scholar 

  97. Minthon L, Gustafson L, Dalfelt G, et al. Oral tetrahydroaminoacridine treatment of Alzheimer’s disease evaluated clinically and by regional cerebral blood flow and EEG. Dementia 1993; 4(1): 32–42

    PubMed  CAS  Google Scholar 

  98. Wilcock GK, Surmon DJ, Scott M, et al. An evaluation of the efficacy and safety of tetrahydroaminoacridine (THA) without lecithin in the treatment of Alzheimer’s disease. Age Ageing 1993; 22(5): 316–24

    PubMed  CAS  Google Scholar 

  99. Knapp MJ, Knopman DS, Solomon PR, et al. A 30-week randomized controlled trial of high-dose tacrine in patients with Alzheimer’s disease. JAMA 1994; 271(13): 985–91

    PubMed  CAS  Google Scholar 

  100. Maltby N, Broe GA, Creasey H, et al. Efficacy of tacrine and lecithin in mild to moderate Alzheimer’s disease: double blind trial [see comments]. BMJ 1994; 308(6933): 879–83

    PubMed  CAS  Google Scholar 

  101. Chatellier G, Lacomblez L. Tacrine (tetrahydroaminoacridine; THA) and lecithin in senile dementia of the Alzheimer type: a multicentre trial. BMJ 1990; 300: 495–9

    PubMed  CAS  Google Scholar 

  102. Gauthier S, Bouchard R, Lamontagne A, et al. Tetrahydroaminoacridine-lecithin combination treatment in patients with intermediate-stage Alzheimer’s disease. N Engl J Med 1990; 322: 1272–6

    PubMed  CAS  Google Scholar 

  103. Eagger SA, Levy R, Sahakian BJ. Tacrine in Alzheimer’s disease. Lancet 1991; 337: 989–93

    PubMed  CAS  Google Scholar 

  104. Schneider LS, Farlow MR, Henderson VW, et al. Effects of estrogen replacement therapy on response to tacrine in patients with Alzheimer’s disease. Neurology 1996; 46(6): 1580–4

    PubMed  CAS  Google Scholar 

  105. Rogers SI, Friedhoff. The efficacy and safety of donepezil in patients with Alzheimer’s disease: results of a US multicentre, randomized, double-blind, placebo-controlled trial. Dementia 1996; 7: 293–303

    PubMed  CAS  Google Scholar 

  106. Campi N, Todeschini GP, Scarzella L. Selegiline versus L-acetylcarnitine in the treatment of Alzheimer-type dementia. Clin Ther 1990; 12(4): 306–14

    PubMed  CAS  Google Scholar 

  107. Falsaperla A, Preti PAM, Oliani C. Selegiline versus oxiracetam in patients with Alzheimer-type dementia. Clin Ther 1990; 12(5): 376–84

    PubMed  CAS  Google Scholar 

  108. Monteverde A, Gnemmi P, Rossi F, et al. Selegiline in the treatment of mild to moderate Alzheimer-type dementia. Clin Ther 1990; 12(4): 315–22

    PubMed  CAS  Google Scholar 

  109. Piccinin GL, Finali G, Massimo P. Neuropsychological effects of L-deprenyl in Alzheimer’s type dementia. Clin Neuropharmacol 1990; 13(2): 147–63

    PubMed  CAS  Google Scholar 

  110. Burke WJ, Ranno AE, Roccaforte WH, et al. L-deprenyl in the treatment of mild dementia of the Alzheimer type: preliminary results. J Am Geriatr Soc 1993; 41(4): 367–70

    PubMed  CAS  Google Scholar 

  111. Marin DB, Bierer LM, Lawlor BA, et al. L-deprenyl and physostigmine for the treatment of Alzheimer’s disease. Psychiatry Res 1995; 58(3): 181–9

    PubMed  CAS  Google Scholar 

  112. Sano M, Ernesto C, Thomas RG, et al. A controlled trial of selegiline, alpha-tocopherol, or both as treatment for Alzheimer’s disease. N Engl J Med 1997; 24: 1216–22

    Google Scholar 

  113. Corona GL, Cucchi ML, Frattini P, et al. Clinical and biochemical responses to therapy in Alzheimer’s disease and multiinfarct dementia. Eur Arch Psychiatry Neurol Sci 1989; 239: (2): 79–86

    PubMed  CAS  Google Scholar 

  114. Parnetti L, Abate G, Bartorelli L, et al. Multicentre study of 1-alpha-glyceryl-phosphorylcholine vs ST200 among patients with probable senile dementia of Alzheimer’s type. Drugs Aging 1993; 3(2): 159–64

    PubMed  CAS  Google Scholar 

  115. Parnetti L, Ambrosoli L, Abate G, et al. Posatirelin for the treatment of late-onset Alzheimer’s disease: a double-blind multicentre study vs citicoline and ascorbic acid. Acta Neurol Scand 1995; 92(2): 135–40

    PubMed  CAS  Google Scholar 

  116. Huff FJ, Besipirdine Study Group. Preliminary evaluation of besipirdine for the treatment of Alzheimer’s disease. Ann N Y Acad Sci 1996; 777: 410–4

    PubMed  CAS  Google Scholar 

  117. Dehlin O, Hedenrud B, Jansson P, et al. A double-blind comparison of alaproclate and placebo in the treatment of patients with senile dementia. Acta Psychiatr Scand 1985; 71: 190–6

    PubMed  CAS  Google Scholar 

  118. Schneider LS, Olin JT. Overview of clinical trials of hydergine in dementia. Arch Neurol 1994; 51(8): 787–98

    PubMed  CAS  Google Scholar 

  119. Schneider F, Popa R, Mihalas G, et al. Superiority of antagonicstress composition versus nicergoline in gerontopsychiatry. Ann N Y Acad Sci 1994; 717: 332–42

    PubMed  CAS  Google Scholar 

  120. Saletu B, Paulus E, Linzmayer L, et al. Nicergoline in senile dementia of Alzheimer type and multi-infarct dementia: a double-blind, placebo-controlled, clinical and EEG/ERP mapping study. Psychopharmacology 1995; 117(4): 385–95

    PubMed  CAS  Google Scholar 

  121. Aguglia E, Caraceni T, Genitrini S, et al. Comparison of teniloxazine and piracetam in Alzheimer-type or vascular dementia. Curr Ther Res 1995; 56(3): 250–7

    Google Scholar 

  122. Marcusson J, Rother M, Kittner B, et al. A 12-month, randomized, placebo-controlled trial of propentofylline (HWA 285) in patients with dementia according to DSM III-R. Dementia 1997; 8: 320–8

    CAS  Google Scholar 

  123. Knezevic S, Mubrin Z, Risberg J, et al. Pyritinol treatment of SDAT patients: evaluation by psychiatric and neurological examination, psychometric testing and rCBF measurements. Int Clin Psychopharmacol 1989; 4: 25–38

    PubMed  CAS  Google Scholar 

  124. Fischhof PK, Saletu B, Ruther E, et al. Therapeutic efficacy of pyritinol in patients with senile dementia of the Alzheimer type (SDAT) and multi-infarct dementia (MID). Neuropsychobiology 1992; 26(1-2): 65–70

    PubMed  CAS  Google Scholar 

  125. McLachlan DR, Smith WL, Kruck TP. Desferrioxamine and Alzheimer’s disease: video home behavior assessment of clinical course and measures of brain aluminum. Ther Drug Monit 1993; 15:(6): 602–7

    PubMed  CAS  Google Scholar 

  126. Rogers J, Kirby LC, Hempelman SR, et al. Clinical trial of indomethacin in Alzheimer’s disease. Neurology 1993; 43: 1609–11

    PubMed  CAS  Google Scholar 

  127. Ban TA, Morey L, Aguglia E, et. al. Nimodipine in the treatment of old age dementias. Prog Neuropsych Biol Psychiatry 1990; 14:(4): 525–51

    CAS  Google Scholar 

  128. Tollefson GD. Short-term effects of the calcium channel blocker nimodipine (Bay-e-9736) in the management of primary degenerative dementia. Soc Biol Psychiatry 1990; 27: 1133–42

    CAS  Google Scholar 

  129. Fischhof PK. Divergent neuroprotective effects of nimodipine in PDD and MID provide indirect evidence of disturbances in Ca2+ homeostasis in dementia [see comments]. Methods Find Exp Clin Pharmacol 1993; 15(8): 549–55

    PubMed  CAS  Google Scholar 

  130. Rai G, Wright G, Scott L, et al. Double-blind, placebo controlled study of acetyl-1-carnitine in patients with Alzheimer’s dementia. Curr Med Res Opin 1990; 11(10): 638–47

    PubMed  CAS  Google Scholar 

  131. Livingston G, Sax KB, McClenahan Z, et al. Acetyl-1-carnitine in dementia. Int J Geriatr Psychiatry 1991; 6(12): 853–60

    Google Scholar 

  132. Sano M, Bell K, Cote L, et al. Double-blind parallel design pilot study of acetyl levocarnitine in patients with Alzheimer’s disease. Arch Neurol 1992; 49: 1137–41

    PubMed  CAS  Google Scholar 

  133. Lampe TH, Norris J, Risse SC, et al. Therapeutic potential of thyrotropin-releasing hormone (TRH) and lecithin coadministration in Alzheimer’s disease [abstract]. Neurobiol Aging 1990; 11: 346

    Google Scholar 

  134. Molchan SE, Mellow AM, Hill JL, et al. The effects of thyrotropin-releasing hormone and scopolamine in Alzheimer’s disease and normal volunteers. J Psychopharmacol 1992; 6:(4): 489–500

    PubMed  CAS  Google Scholar 

  135. Talland GA. Deranged memory. New York: Academic Press, 1965

    Google Scholar 

  136. Weinberg J, Diller L. On reading newspapers by hemiplegics: denial of visual disability. Proceedings of the 76th Annual Convention of the American Psychological Association: 1968; 3: 655–6

    Google Scholar 

  137. War Department. Army individual test battery: manual of directions and scoring. Washington DC: War Department, Adjutant General’s Office, 1944

    Google Scholar 

  138. Milner B. Interhemispheric differences in the localization of psychological processes in man. Br Med Bull 1971; 27: 272–7

    PubMed  CAS  Google Scholar 

  139. Barbizet J, Cany E. Clinical and psychometrical study of a patient with memory disturbances. Int J Neurol 1968; 7: 44–54

    PubMed  CAS  Google Scholar 

  140. Carlesimo GA, Fadda L, Lorusso S, et al. Verbal and spatial memory spans in Alzheimer’s and multi-infarct dementias. Acta Neurol Scand 1994; 89: 132–8

    PubMed  CAS  Google Scholar 

  141. Simard M. Étude comparative des altérations de la mémoire de travail dans la maladie de Parkinson et l’ataxie de Friedreich: implication des processus de l’administrateur central [Ph.D. dissertation]. Montréal: Universitaire du Québec à Montréal, 1997

    Google Scholar 

  142. Simard M, Melançon S, Panisset M. Visuospatial working memory deficits in Friedreich’s ataxia [abstract no. P127]. American Neuropsychiatric Association Eigth Annual Meeting Program and Abstracts. J Neuropsychiatry Clin Neurosci 1997; 9(1): 167

    Google Scholar 

  143. Buschke H. Cued recall in amnesia. J Clin Neuropsychol 1984; 6: 433–40

    PubMed  CAS  Google Scholar 

  144. Fuld PA. Guaranteed stimulus-processing in the evaluation of memory and learning. Cortex 1980; 16: 255–72

    PubMed  CAS  Google Scholar 

  145. Taylor EM. The appraisal of children with cerebral deficits. Cambridge (MA): Harvard University Press, 1959

    Google Scholar 

  146. Rey A. L’examen clinique en psychologie. Paris: Presses Universitaires de France, 1964

    Google Scholar 

  147. Kendrick DC, Gibson AJ, Moyes ICA. The revised Kendrick battery: clinical studies. Br J Soc Clin Psychol 1979; 18: 329–40

    PubMed  CAS  Google Scholar 

  148. Benton AL. The revised visual retention test. 4th ed. New York: Psychological Corporation, 1974

    Google Scholar 

  149. Benton AL, Hamsher K de S, Varney NR, et al. Contributions to neuropsychological assessment. Oxford: Oxford University Press, 1978, 1983

    Google Scholar 

  150. Benton AL, Hamsher K de S. Multilingual aphasia examination. Revised 1978. Iowa City: University of Iowa, 1976

    Google Scholar 

  151. Wilson RS, Kaszniak AW, Fox JH. Remote memory in senile dementia. Cortex 1981; 17: 41–8

    PubMed  CAS  Google Scholar 

  152. Goodglass H, Kaplan E. The assessment of aphasia and related disorders. Philadelphia: Lea and Febiger, 1972

    Google Scholar 

  153. Kaplan E, Goodglass H, Weintraub S. The Boston naming test. San Antonio: The Psychological Corporation, Harcourt, Brace and Company, 1978

    Google Scholar 

  154. Borod JC, Goodglass H, Kaplan E. Normative data on the Boston diagnostic aphasia examination, parietal lobe battery and the Boston naming test. J Clin Neuropsychol 1980; 2(3): 209–15

    Google Scholar 

  155. Schneider LS, Tariot PN. Emerging drugs for Alzheimer’s disease: mechanisms of action and prospects for cognitive enhancing medications [review]. Med Clin North Am 1994; 78(4): 911–34

    PubMed  CAS  Google Scholar 

  156. Folstein MR, Folstein S, McHugh PR. Mini-mental state: a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975; 12: 189–98

    PubMed  CAS  Google Scholar 

  157. Rosen WG, Mohs RC, Davis KL. A new rating scale for Alzheimer’s disease. Am J Psychiatr 1984; 141(11): 1356–64

    PubMed  CAS  Google Scholar 

  158. Shader RI, Harmatz JS, Salzman C. A new scale for clinical assessment in geriatric populations: Sandoz clinical assessment-geriatric (SCAG). J Am Geriatr Soc 1974; 22(3): 107–13

    PubMed  CAS  Google Scholar 

  159. Yesavage JA, Adey M, Werner PD. Development of a geriatric behavioral self-assessment scale. J Am Geriatr Soc 1981; 24(6): 285–8

    Google Scholar 

  160. Blessed G, Tomlinson BE, Roth M. The association between quantitative measures of dementia and of senile change in the cerebral grey matter of elderly subjects. Br J Psychiatr 1968; 114: 797–811

    CAS  Google Scholar 

  161. Gottfried CG, Brane G, Gullberg B, et al. A new rating scale for dementia syndromes. Arch Gerontol Geriatr 1982; 1: 311–30

    Google Scholar 

  162. Reisberg B, Ferris SH, De Leon MJ, et al. The global deterioration scale for assessment of primary degenerative dementia. Am J Psychiatr 1982; 139(9): 1136–9

    PubMed  CAS  Google Scholar 

  163. Wechsler D. Wechsler memory scale manual. San Antonio (TX): The Psychological Corporation, 1974

    Google Scholar 

  164. Wechsler D, Stone CP. Wechsler memory scale II manual. New York: The Psychological Corporation, 1974

    Google Scholar 

  165. Wechsler D. Wechsler memory scale — revised manual. San Antonio (TX): The Psychological Corporation, 1987

    Google Scholar 

  166. Mohr E, Feldman H, Gauthier S. Canadian guidelines for the development of antidementia therapies: a conceptual summary. Can J Neurol Sci 1995; 22(1): 62–71

    PubMed  CAS  Google Scholar 

  167. Little AG, Volans PJ, Hemsley DR, et al. The retention of new information in senile dementia. Br J Clin Psychiatr 1986; 25: 71–2

    Google Scholar 

  168. Fuld P, Masur DM, Blau AD, et al. Object-memory evaluation for prospective detection of dementia in normal functioning elderly: predictive and normative data. J Clin Exp Neuropsychol 1990; 12(40): 520–8

    PubMed  CAS  Google Scholar 

  169. Buschke H. Selective reminding for analysis of memory and learning. J Verbal Learn Verbal Behav 1973; 12: 543–50

    Google Scholar 

  170. Buschke H, Fuld PA. Evaluating storage, retention, and retrieval in disordered memory and learning. Neurology 1974; 24: 1019–25

    PubMed  CAS  Google Scholar 

  171. Tulving E, Thompson EM. Encoding specificity and retrieval processes in episodic memory. Psychol Rev 1973; 80: 352–73

    Google Scholar 

  172. Snodgrass JG, Vanderwart MA. A standardized set of 260 pictures: norms for name agreement, familiarity, and visual complexity. J Exp Psychol Hum Learn Mem 1980; 6: 174–215

    CAS  Google Scholar 

  173. Masur DM, Fuld PA, Blau H, et al. Predicting development of dementia in the elderly with the selective reminding test. J Clin Exp Neuropsychol 1990; 12(40): 529–38

    PubMed  CAS  Google Scholar 

  174. Masur DM, Sliwinski M, Lipton RB, et al. Neuropsychological prediction of dementia and the absence of dementia in healthy elderly persons. Neurology 1994; 44: 1427–32

    PubMed  CAS  Google Scholar 

  175. Petersen RC, Smith GE, Ivnik RJ, et al. Memory function in very early Alzheimer’s disease. Neurology 1994; 44: S67–72

    Google Scholar 

  176. Crystal H, Dickson D, Fuld P, et al. Clinico-pathologic studies in dementia: nondemented subjects with pathologically con-finned Alzheimer’s disease. Neurology 1988; 38: 1682–7

    PubMed  CAS  Google Scholar 

  177. Gibson AJ, Moyes ICA, Kendrick D. Cognitive assessment in the elderly long-stay patient. Br J Psychiatry 1980; 137: 551–7

    PubMed  CAS  Google Scholar 

  178. Skelton-Robinson M, Telford R. Observations on the object learning test of the Kendrick battery for the detection of dementia. Br J Clin Psychol 1982; 21(2): 146–8

    Google Scholar 

  179. McKhann G, Drachman D, Folstein M, et al. Clinical diagnosis of Alzheimer’s disease: report of the NINCDS-ADRDA work group under the auspices of the Department of Health and Human Services task force on Alzheimer’s disease. Neurology 1984; 34: 939–44

    PubMed  CAS  Google Scholar 

  180. Squire LR. Remote memory as affected by aging. Neuropsychologia. 1974; 12: 429–35

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Psychiatry, Baycrest Centre for Geriatric Care, 3560 Bathurst Street, North York, Ontario, M6A 2E1, Canada

    Martine Simard & Robert van Reekum

  2. Division of Geriatric Psychiatry, Department of Psychiatry, University of Toronto, Toronto, Ontario, Canada

    Martine Simard & Robert van Reekum

Authors
  1. Martine Simard
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Robert van Reekum
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Simard, M., van Reekum, R. Memory Assessment in Studies of Cognition-Enhancing Drugs for Alzheimer’s Disease. Drugs & Aging 14, 197–230 (1999). https://doi.org/10.2165/00002512-199914030-00004

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00002512-199914030-00004

Keywords

Search

Navigation